

Living with Advanced Non-Small Cell Lung Cancer

How to Receive CE Credit

To earn free CE credit for watching this program, you must complete this test online.

Go to www.discoveryhealthCME.com and follow the instructions to complete the post-test and evaluation online. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and you will be able to print the appropriate credit certificate right from your computer.

CE Test Questions

1. Cisplatin plus pemetrexed is now included in the NCCN guidelines as a category 1 option for first-line therapy in patients who meet criteria, including performance status 0 to 1 and which of the following?
 - a. Squamous histology
 - b. Nonsquamous histology, including adenocarcinoma
 - c. Advanced NSCLC, any histopathologic type
 - d. Non-metastatic NSCLC only
2. Treatment with a combination of bevacizumab and chemotherapy:
 - a. Should be continued indefinitely, once started
 - b. Requires consideration of tumor histology
 - c. Is not included in current NCCN guidelines for NSCLC
 - d. Has not been shown to be effective in patients with advanced NSCLC
3. The presence of a certain biomarker (a type of EGFR mutation) means that erlotinib:
 - a. Should not be used
 - b. Is an option for monotherapy if patients meet certain other criteria
 - c. Should be used only in combination with chemotherapy
 - d. Should be used only if the tumor has nonsquamous histology
4. If a patient complains of fatigue as a result of NSCLC treatment, the first response should be:
 - a. Begin treatment for anemia
 - b. Reduce the dose of the NSCLC therapy
 - c. Begin treatment for depression
 - d. Evaluate the cause of fatigue

5. Many patients with NSCLC, even those who respond well to aggressive treatment, will reach a point when cancer recurs or progresses and aggressive treatment is no longer the best choice. Regarding the decision to halt aggressive treatment, which of the following is correct?
- a. The decision to move to “supportive care” means that all treatment should be stopped, except opioids to control pain.
 - b. If aggressive treatment is to be stopped, efforts to prolong the patient’s life should no longer be made.
 - c. Once the decision has been made to stop aggressive treatment, the focus is usually on prolonging the patient’s life as long as possible while maintaining the best possible quality of life
 - d. When aggressive treatment is stopped, patients should be started on antidepressant medication as a routine preventive measure.

CE Evaluation

Living with Advanced Non-Small Cell Lung Cancer

1. The program content helped me to achieve the following objectives:

Describe new systemic treatment regimens for patients with advanced non-small cell lung cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

List criteria for selecting the best treatment regimen for select patients with advanced non-small cell lung cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

Identify strategies to help decrease treatment-related side effects of systemic therapy for non-small cell lung cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

Describe decision-making paradigms for selecting palliative therapies in patients with advanced non-small cell lung cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

2. Time spent completing this activity?

< 30 min 30 min 45 min 1 hr 1.5 hrs .>1.5 hrs

Rate the extent to which you agree or disagree:

3. I was satisfied with the overall quality of this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

4. This activity addressed issues that will help me improve my professional competence and/or performance.

Strongly Agree Agree Undecided Disagree Strongly Disagree

5. You will make a change in your practice as a result of participation in this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

6. The activity presented scientifically rigorous, unbiased, and balanced information.

Strongly Agree Agree Undecided Disagree Strongly Disagree

7. Individual presentations were free of commercial bias.

Strongly Agree Agree Undecided Disagree Strongly Disagree

8. Information presented in this activity is applicable to my professional role.

Strongly Agree Agree Undecided Disagree Strongly Disagree

9. Which ONE of the following best describes the impact of this activity on you:

- a. I plan to incorporate these updates in cancer management into my practice.
- b. I do not plan to incorporate these updates in cancer management into my practice.
- c. Not applicable to my healthcare role.

10. For Question #9, if you selected "B" please list any factors that may be acting as barriers to implementing change.

11. If commercial bias was noted, please explain.

12. To improve your professional competence or performance, on what oncology topics would you like future NCCN education programs to be focused?

13. Additional Feedback.